Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ligand Pharmaceuticals Incorporated
< Previous
1
2
Next >
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
April 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
April 08, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
April 03, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
February 16, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
January 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
December 12, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
December 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand To Report Third Quarter 2023 Financial Results On November 8
October 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
September 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Appoints Martine Zimmermann to its Board of Directors
September 26, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
September 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
September 21, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
September 18, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
July 27, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand To Report Second Quarter 2023 Financial Results On August 8
July 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
July 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 16, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Reports First Quarter 2023 Financial Results
May 04, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
April 24, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tickers
LGND
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.